Previous Close | 6.540 |
Open | 6.540 |
Bid | 6.360 x 0 |
Ask | 6.370 x 0 |
Day's Range | 6.360 - 6.540 |
52 Week Range | 5.200 - 8.780 |
Volume | |
Avg. Volume | 39,627,102 |
Market Cap | 77.847B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | 11.47 |
EPS (TTM) | 0.570 |
Earnings Date | Mar 20, 2024 |
Forward Dividend & Yield | 0.28 (4.28%) |
Ex-Dividend Date | Sep 07, 2023 |
1y Target Est | 9.78 |
Subscribe to Yahoo Finance Plus to view Fair Value for 1093.HK
Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China. The combination of Nirmatrelvir and Ritonavir sold under the brand name Paxlovid, an oral small molecule developed by pharmaceutical company Pfizer, is used to treat patients suffering from mild to moderate COVID-19 symptoms and who are at the risk of disease progression. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Cli
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that an abstract featuring SYSA1801 (EO-3021) Phase 1 clinical data has been selected for a poster presentation and poster discussion at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago,